智通财经APP获悉，部分创新药概念股早盘走高，截至发稿，药明巨诺-B(02126)涨8.77%，报3.35港 元；科济药业-B(02171)涨3.8%，报18.87港元；北海康成-B(01228)涨3.38%，报2.45港元；君实生物 (01877)涨2.29%，报24.1港元。 值得注意的是，备受瞩目的百万CAR-T细胞疗法——复星凯瑞的阿基仑赛注射液、药明巨诺的瑞基奥仑 赛注射液、合源生物的纳基奥仑赛注射液、驯鹿生物的伊基奥仑赛注射液、恺兴生命科技的泽沃基奥仑 赛注射液均被纳入首批商保创新药目录。 消息面上，2025年国家基本医疗保险、生育保险和工伤保险药品目录是国家医保局成立以来的第8次调 整。本次目录调整新增114种药品，其中50种为1类创新药。据智通财经报道，复星医药的芦沃美替尼片 进入2025年医保目录，北海康成的注射用维拉苷酶β进入商保创新药目录。 ...

国家医保局等部门印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新 药品目录》，自2026年1月1日起正式执行。 国家医保局成立以来医保药品目录已调整8次，本次医保药品目录调整新增114种药品，其中50种为1类 创新药。首版商保创新药目录共纳入19种药品，既有CAR-T等肿瘤治疗药品，也有社会关注度较高的阿 尔茨海默病治疗药品。 恒生医药ETF（159892）聚焦创新药产业，在港交所18A制度优势下覆盖众多创新标的（百济神州、信 达生物、康方生物等），有望受益于医保目录的更新和美联储降息。 （文章来源：每日经济新闻） 具体来看，复星医药的芦沃美替尼片进入2025年医保目录，北海康成的注射用维拉苷酶β进入商保创新 药目录。同时，5款CAR-T药进入商保创新药目录，分别是复星凯瑞的阿基仑赛注射液、药明巨诺的瑞 基奥仑赛注射液、合源生物的纳基奥仑赛注射液、驯鹿生物的伊基奥仑赛注射液、科济药业的泽沃基奥 仑赛注射液。 从药企角度来看，纳入医保+商保的创新药大多处于放量初期，随着政策红利释放，纳入医保、商保目 录的创新药有望快速放量。商保的逐步推广也有望增加创新药费用的支付来源，促进创新药在支付 ...

说完昨天晚上的消息面，接下来我们继续聊市场，那今天市场到底会怎么走？首先在这里面说一下我的 看法，我认为在周末利好的影响之下，今天市场出现高开的概率比较高，但是注意一点，如果今天市场 出现明显大幅高开的话，那么要注意点大幅高开之后呢市场会有回踩动作，只有扛住早盘半小时到一小 时的回踩，那么市场才算真正稳得住，才有机会走出新的上涨行情。而且也不能因为周末两天给很多的 利好消息，大家情绪上就太乐观。我这里面不是看空市场，我强调一点是在于一方面利好消息出来之后 情绪上会有反馈，但是最终决定于市场的是资金到底认可不认可，资金真正认可了，市场才能够走出新 的上涨走势，所以这才是核心点。所以早盘大家要注意几个信号，第一个大幅高开之后回踩动作回踩幅 度不能超过50%，最好是在50%以上，如果超过50%的话就有一点走弱了，这就要注意了。另外第二点 回踩完成之后，第二次上攻的时候成交量也要放大市场，这里面要给出强势状态，一旦这种符合的话， 那么就代表着已经确认了新的上涨行情已经开启了，这个时候就是我们进考虑呢继续加仓的这种动作。 所以综合来看的话，今天实际上要看这些细节，但不管怎么说，周末交易出来之后，包括在上周五我们 也讲了 ...

恒瑞医药 20251205 摘要 恒瑞医药坚持创新和国际化双轮驱动战略，聚焦肿瘤、代谢、心血管、 自免及退行性疾病等领域，通过技术创新和"借船出海"策略拓展国际 市场，自 2023 年以来已达成 12 笔对外许可交易，总金额近 280 亿美 元。 公司通过建立和迭代细胞治疗、核酸药物、基因治疗及蛋白降解剂等新 兴技术平台，并注重创新模块的基本功，组合成差异化的治疗方案，例 如在代谢领域开发 PCSK9 抑制剂和长效小分子疗法。 恒瑞医药在肿瘤治疗领域构建四位一体的协同创新疗法，包括免疫治疗 （PD-1、细胞因子、细胞治疗）、靶向化疗（ADC、多肽-核素连接）、 支持治疗和精准治疗（KRAS 抑制剂），并探索融合不同技术平台以实 现更高效的肿瘤免疫反应。 在代谢疾病领域，恒瑞已有多个糖尿病口服产品上市，并计划于 2026 年推出减重药 9,531，该产品临床数据显示出良好的疗效和安全性，公 司正致力于解决现有减重药的副作用和依从性问题，并研究新型给药方 式。 Q&A 恒瑞医药未来的发展战略是什么？ 恒瑞医药近年来在研发投入和国际化方面取得了哪些成就？ 截至目前，恒瑞医药累计投入研发费用已超过 500 亿人民币， ...

Summary of Key Points from Conference Call Records Industry and Company Overview - The conference call discusses the global economic landscape, focusing on the implications of U.S. monetary policy, U.S.-China relations, and the technology sector's development in 2026 [1][2][4]. Core Insights and Arguments U.S. Monetary Policy - The Federal Reserve is expected to maintain a passive easing policy, with potential impacts on liquidity influenced by Trump's announcement of the next Fed chair, which could benefit tech stocks but with limited sustainability [1][2]. - A key focus is on the timing of the Fed's shift to active easing, which historically has been favorable for U.S. equities [3]. U.S.-China Relations - 2026 is highlighted as a pivotal year for U.S.-China relations, with significant events such as Trump's potential visit to China and the need for a trade agreement by September to gain support from key voter demographics [5][6]. - The Chinese government is likely to implement policies to guide long-term capital into the market and support technological development in response to U.S. competition [4]. Domestic Policy Directions - China's domestic policies will become more proactive in addressing international competition, focusing on developing new productive forces and reducing reliance on high technology [7][11]. - The emphasis will be on enhancing the value of domestic industries and addressing the challenges posed by U.S. policies [11][12]. Investment Opportunities - Key investment opportunities in 2026 include sectors related to AI applications, AR technology, humanoid robotics, consumer electronics, and innovative pharmaceuticals [13]. - The focus on new energy supply chains, including critical materials like lithium and silicon, is emphasized as a strategic area for investment [12][37]. Risks and Market Dynamics - The Nasdaq's current valuation is noted to be significantly lower than during the Obama administration, despite higher ROE, indicating potential for recovery as the Fed shifts to active easing [3]. - The technology sector is experiencing volatility not primarily due to AI issues but rather due to market share shifts among companies, which could lead to increased investment and technological advancement in the long term [3]. Other Important but Potentially Overlooked Content Economic Indicators - The Shanghai Composite Index and the RMB/USD exchange rate are identified as critical indicators for monitoring China's economic health and policy effectiveness [8]. - The anticipated annual increase in the Shanghai Composite Index is projected to be between 10% and 20%, with a focus on maintaining a low volatility environment [8]. Housing Market Outlook - The housing market is expected to remain in a correction phase, with rental yields significantly lower than mortgage rates, making renting more attractive than buying [16]. Consumer and Fiscal Policies - China's consumer and fiscal policies are designed to ensure social stability amid geopolitical tensions, with limited scope for aggressive consumer spending initiatives [14][15]. Structural Changes in the Economy - The ongoing structural changes in China's economy, particularly in the real estate sector, are leading to a decline in disposable income growth and consumer sentiment, impacting overall economic stability [23]. Strategic Focus Areas - The conference highlights the importance of focusing on industries that can enhance China's competitive edge in global markets, particularly in technology and energy sectors [27][34]. This summary encapsulates the key points discussed in the conference call, providing insights into the strategic directions and investment opportunities within the context of the evolving global economic landscape.

Core Viewpoint - The National Healthcare Security Administration (NHSA) has announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and introduces the Commercial Health Insurance Innovative Drug Catalog for 2025, marking the eighth adjustment since the NHSA's establishment and the first addition of a commercial insurance catalog [1][2]. Group 1: Drug Catalog Adjustments - A total of 114 new drugs have been added to the national medical insurance catalog, including 50 Class 1 innovative drugs, while 29 drugs have been removed due to lack of clinical supply or better alternatives [2]. - The new catalog includes drugs addressing significant diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as treatments for rare diseases and chronic conditions like diabetes and autoimmune diseases [2]. - The overall success rate for the newly added innovative drugs is 88%, an increase from 76% in 2024 [2]. Group 2: Market Impact and Growth Potential - The inclusion of innovative drugs in the insurance catalog is expected to lead to rapid revenue growth for these drugs, benefiting patients and driving growth for related pharmaceutical companies [3]. - Zhongtai Securities predicts that the innovative drug market will continue to thrive, noting that the current market conditions have returned to a relatively reasonable and low position, enhancing investment safety margins and return values [3]. Group 3: Company Announcements - Green Leaf Pharmaceutical has successfully included five new products in the national medical insurance and commercial health insurance catalogs, including MiMeiXin and ZhanBiJia [4]. - Fuhong Hanlin announced that its product Fuzhining has been included in the national medical insurance catalog for 2025 [5]. - Innovent Biologics reported that seven of its innovative products have been successfully added to the new national medical insurance catalog, including the PD-1 monoclonal antibody drug [6].

Core Insights - The company 奥赛康 (002755.SZ) announced that its product 利厄替尼片 (brand name: 奥壹新) has been included in the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, as per the notification from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security dated December 7, 2025 [1] Group 1 - 利厄替尼 is a third-generation EGFR TKI developed collaboratively by the Shanghai Institute of Materia Medica, the Guangzhou Institute of Biomedicine and Health, and 江苏奥赛康药业有限公司, specifically targeting EGFR mutation non-small cell lung cancer (NSCLC) [1] - The inclusion of 利厄替尼片 in the national medical insurance catalog is expected to enhance the product's accessibility, facilitating market promotion and positively impacting sales [1]

Macroeconomic Highlights - The State Council held a meeting on December 5 to discuss further energy conservation and carbon reduction efforts, emphasizing the importance of these initiatives in achieving carbon peak and carbon neutrality goals [1] - The meeting highlighted the need for higher quality and more effective energy conservation and carbon reduction work, enhancing internal motivation and improving market mechanisms [1] Securities Industry - On December 6, the Chairman of the China Securities Regulatory Commission (CSRC), Wu Qing, addressed the eighth member meeting of the China Securities Association, emphasizing the responsibility of the financial sector in national development [2] - Wu Qing indicated that regulatory policies would encourage differentiated supervision, with a focus on loosening capital space and leverage limits for high-quality institutions to improve capital efficiency [2] Insurance Sector - On December 5, the Financial Regulatory Bureau announced adjustments to risk factors for insurance companies, lowering risk factors for long-term holdings of stocks in the CSI 300 index and STAR Market [3] - The new regulations also reduce premium and reserve risk factors for export credit and overseas investment insurance, while requiring insurers to enhance internal controls and strengthen solvency management [3] Gold Reserves - As of November 2025, China's gold reserves reached 74.12 million ounces (approximately 2,305.39 tons), marking an increase of 30,000 ounces (about 0.93 tons) and continuing a streak of 13 consecutive months of gold accumulation [4] Regulatory Developments for Listed Companies - On December 5, the CSRC released a draft for public consultation on the "Regulations on the Supervision and Management of Listed Companies," aimed at enhancing corporate governance, information disclosure, and investor protection [5] - This draft represents the first specialized administrative regulation for the supervision of listed companies in China [5] Pharmaceutical Sector - The 2025 National Medical Insurance Drug List and the first version of the commercial insurance innovative drug list were released, adding 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, up from 76% in 2024 [6] - The new lists include advanced treatments such as CAR-T and T-cell therapies, as well as drugs for rare diseases that are not currently covered by basic medical insurance [6] Company News - Muxi Co., Ltd. reported a final online issuance success rate of 0.03348913% [10] - China Pacific Insurance's Vice President Yu Ze is under investigation for serious violations of discipline and law [10] - Guolian Aviation's controlling shareholder and chairman Wang Zengduo has been released from detention [10] - Annie Co., Ltd. is planning a change in control, with stock resuming trading on December 8 [10] - ST Tianrui has terminated plans for a change in control, with stock resuming trading on December 8 [10] - Several pharmaceutical companies, including Heng Rui Medicine and Junshi Bioscience, have successfully added multiple drugs to the national medical insurance directory [10]

Group 1 - In the first 11 months of the year, 626 out of 650 comparable QDII funds saw an increase in net value, representing 96.3% of the total [1] - The innovative pharmaceutical sector has rebounded, leading to significant gains for funds heavily invested in this area, with the top-performing fund, Huatai Fuhong Hong Kong Advantage Selection Mixed A/C, achieving a return of 141.57% [1] - The fund's investment strategy focuses on innovative drugs with global competitiveness and high barriers in the medical equipment sector [1] Group 2 - Nine QDII funds recorded gains exceeding 87% in the first 11 months, with four funds from E Fund Management achieving over 92% returns [2] - The top holdings of these funds include companies like Fuhong Hanlin, Xinda Biopharmaceutical, and Keren Biotech [2] - Other high-performing funds include Chuangjin Hexin Global Pharmaceutical Biotechnology Stock Initiation A and C, and GF CSI Hong Kong Innovative Medicine ETF, with returns of 100.32% and 99.68% respectively [2] Group 3 - The Industrial Bank New Economy Mixed Dollar fund, managed by Zhao Bei, has top holdings including Xinda Biopharmaceutical and Jinfang Pharmaceutical [3] - Funds focused on oil and gas, as well as real estate, have underperformed, particularly those tracking the FTSE Saudi Arabia Index [3] Group 4 - The top 10 QDII funds by performance in the first 11 months include Huatai Fuhong Hong Kong Advantage Selection Mixed A, with a return of 141.57%, and E Fund Global Pharmaceutical Industry Mixed C, with a return of 95.67% [4] - The performance of these funds highlights the strong returns in the pharmaceutical sector compared to other sectors like oil and real estate [4]

Core Insights - The National Healthcare Security Administration (NHSA) has officially announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and 19 drugs in the first version of the Commercial Health Insurance Innovative Drug Catalog, effective from January 1, 2026 [1][2][3] Industry Summary - The NHSA has adjusted the drug catalog for the eighth time since its establishment, with a total of 949 new drugs added over the years, and the medical insurance fund has spent over 4.6 trillion RMB on negotiated drugs, driving sales exceeding 6 trillion RMB [1][2] - The new catalog includes 50 first-class innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [3] - The inclusion of drugs for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions, addresses gaps in basic medical insurance coverage [2][3] Company-Specific Updates - Green Leaf Pharmaceutical has successfully included five new products in the NHSA's drug catalog, including MiMeiXin® and ZhanBiJia® [4] - Fuhong Hanlin announced that its product Fuzhuoning® has been included in the NHSA's drug catalog for specific indications [5] - Junshi Biosciences reported that its products Tuoyi® and Junshida® have been successfully included in the NHSA's drug catalog [6] - Innovent Biologics has successfully added seven innovative products to the new NHSA drug catalog, including Daboru® and Xindimian® [6]